



Elekta strengthens its position in Brazil with acquisition of Radon Ltda.

Press Release

Stockholm, Sweden, June 19, 2012

Elekta has today acquired Radon Ltda. group, the leading linear accelerator (linac) service company in Brazil. Most of the service contracts held by the company are with clinics that use equipment delivered by Siemens. The acquisition significantly strengthens Elekta's market position, making it the leading organization for installation, service and aftermarket services. Through the acquisition, Elekta's customer base has increased with 25 percent in Brazil.

Brazil is the world's fifth largest country in terms of population. According to the World Health Organization (WHO), cancer incidence is expected to grow significantly mainly due to an increasingly aging population. The Brazilian market for radiation therapy equipment is growing strongly both through private and public expansion initiatives.

"This is great news for radiation therapy customers, both those with Elekta solutions but also customers with solutions from other providers, as they receive assurance that they will be taken good care of," says Antonio Ponce, Vice President, Elekta Latin America. He adds: "Radon is also a platform from which radiation therapy customers across other markets in Latin America can be served."

Radon will continue its current, successful business model and strategy. Denis Colella, a Founder and Partner-Director of Radon, says: "We will maintain our dedication to our customers and thereby keep the Radon name."

Luciano Barros, also a Founder and Partner-Director of Radon, adds: "This transaction enables Radon to greatly increase its capacity. Together, we will be able to grow the service business as well as Elekta's linac market share in Latin America.

Radon is expected to add revenue to Elekta by approximately USD 6 million during the 2012/13 fiscal year. The transaction is forecasted to be accretive to Elekta earnings per share (EPS) during Elekta's fiscal year 2012/13. The transaction structure includes an earn-out element.

###

For further information, please contact:

For further information, please contact:

Håkan Bergström, CFO, Elekta AB (publ)
+46 8 587 25 547, hakan.bergstrom@elekta.com

Stina Thorman, Vice President Corporate Communications, Elekta AB (publ)
08 587 254 37, stina.thorman@elekta.com



Johan Andersson Melbi, Investor Relations Manager, Elekta AB (publ)
+46 8 587 25 415, johan.anderssonmelbi@elekta.com

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07.30 CET on June 19, 2012.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTA. Website: www.elekta.com.